Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prabhat Kumar

Showing results (701-710 of 717) with videos related to

Pageof 72
Sort By:
Plos Pathogens|September 29, 2023
Correction: Effects of chronic exposure to arsenic on the fecal carriage of antibiotic-resistant Escherichia coli among people in rural BangladeshMohammed Badrul Amin, Prabhat Kumar Talukdar, Muhammad Asaduzzaman, et al.
SSM. Mental Health|January 23, 2023
A qualitative exploration of perceived needs and barriers of individuals with schizophrenia, caregivers and clinicians in using mental health applications in Madhya Pradesh, IndiaAmeya P Bondre, Ritu Shrivastava, Harikeerthan Raghuram, et al.
The Journal of Infectious Diseases|July 13, 2007
Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasisSujit Kumar Bhattacharya, Prabhat Kumar Sinha, Shyam Sundar, et al.
Schizophrenia (Heidelberg, Germany)|January 27, 2023
Relapse prediction in schizophrenia with smartphone digital phenotyping during COVID-19: a prospective, three-site, two-country, longitudinal studyAsher Cohen, John A Naslund, Sarah Chang, et al.
Advanced Materials (Deerfield Beach, Fla.)|June 29, 2026
Evolution and Suppression of Spin Cycloid in Epitaxial BiFeO<sub>3</sub> Thin FilmsMaya Ramesh, Xinyan Li, Shashank Ojha, et al.
Lancet (London, England)|January 25, 2011
Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trialShyam Sundar, Prabhat Kumar Sinha, Madhukar Rai, et al.
Indian Journal of Psychological Medicine|January 25, 2021
Impact Evaluation of VKN-NIMHANS-ECHO Model of Capacity Building for Mental Health and Addiction: Methodology of Two Randomized Controlled TrialsChannaveerachari Naveen Kumar, Prabhat Kumar Chand, Narayana Manjunatha, et al.
The Journal of the Association of Physicians of India|March 12, 2026
A Prospective Real-world Study to Assess Safety, Tolerability, and Effectiveness of Imeglimin among People with Type 2 Diabetes Mellitus Who are Intolerant to Metformin (PRISM Study)Prabhat Kumar Agrawal, Ketan K Mehta, Abhisekh Raha, et al.
Joint Bone Spine|February 15, 2022
Established risk loci for systemic lupus erythematosus at NCF2, STAT4, TNPO3, IRF5 and ITGAM associate with distinct clinical manifestations: A Danish genome-wide association studyHenrik Christian Bidstrup Leffers, David Westergaard, Saedis Saevarsdottir, et al.
Digital Health|November 17, 2022
Smartphone digital phenotyping, surveys, and cognitive assessments for global mental health: Initial data and clinical correlations from an international first episode psychosis studyTanvi Lakhtakia, Ameya Bondre, Prabhat Kumar Chand, et al.
Pageof 72

Showing results (701-710 of 717) with videos related to

Sort By:
Pageof 72
Plos Pathogens|September 29, 2023
Correction: Effects of chronic exposure to arsenic on the fecal carriage of antibiotic-resistant Escherichia coli among people in rural BangladeshMohammed Badrul Amin, Prabhat Kumar Talukdar, Muhammad Asaduzzaman, et al.
SSM. Mental Health|January 23, 2023
A qualitative exploration of perceived needs and barriers of individuals with schizophrenia, caregivers and clinicians in using mental health applications in Madhya Pradesh, IndiaAmeya P Bondre, Ritu Shrivastava, Harikeerthan Raghuram, et al.
The Journal of Infectious Diseases|July 13, 2007
Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasisSujit Kumar Bhattacharya, Prabhat Kumar Sinha, Shyam Sundar, et al.
Schizophrenia (Heidelberg, Germany)|January 27, 2023
Relapse prediction in schizophrenia with smartphone digital phenotyping during COVID-19: a prospective, three-site, two-country, longitudinal studyAsher Cohen, John A Naslund, Sarah Chang, et al.
Advanced Materials (Deerfield Beach, Fla.)|June 29, 2026
Evolution and Suppression of Spin Cycloid in Epitaxial BiFeO<sub>3</sub> Thin FilmsMaya Ramesh, Xinyan Li, Shashank Ojha, et al.
Lancet (London, England)|January 25, 2011
Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trialShyam Sundar, Prabhat Kumar Sinha, Madhukar Rai, et al.
Indian Journal of Psychological Medicine|January 25, 2021
Impact Evaluation of VKN-NIMHANS-ECHO Model of Capacity Building for Mental Health and Addiction: Methodology of Two Randomized Controlled TrialsChannaveerachari Naveen Kumar, Prabhat Kumar Chand, Narayana Manjunatha, et al.
The Journal of the Association of Physicians of India|March 12, 2026
A Prospective Real-world Study to Assess Safety, Tolerability, and Effectiveness of Imeglimin among People with Type 2 Diabetes Mellitus Who are Intolerant to Metformin (PRISM Study)Prabhat Kumar Agrawal, Ketan K Mehta, Abhisekh Raha, et al.
Joint Bone Spine|February 15, 2022
Established risk loci for systemic lupus erythematosus at NCF2, STAT4, TNPO3, IRF5 and ITGAM associate with distinct clinical manifestations: A Danish genome-wide association studyHenrik Christian Bidstrup Leffers, David Westergaard, Saedis Saevarsdottir, et al.
Digital Health|November 17, 2022
Smartphone digital phenotyping, surveys, and cognitive assessments for global mental health: Initial data and clinical correlations from an international first episode psychosis studyTanvi Lakhtakia, Ameya Bondre, Prabhat Kumar Chand, et al.
Pageof 72